Research Assistant
Jana has graduated with a M.Sc. in Health Science from the Technical University in Munich, Germany. She has gained research experience in the field of dementia through a project investigating perceived barriers of dementia patients when using augmented reality. An internship at the Kirby Institute at UNSW has brought her to Sydney in 2018, where she has been working on projects exploring reproductive health in women. Jana joined NeuRA in November 2019 as a Research Assistant for the BPSDPlus project and is currently investigating effects of non-pharmacological interventions on BPSD.
After receiving a diagnosis of dementia it is very important that individuals and families have access to support and advice, to help people regain control, plan for the future and carry on living a life that is meaningful to them.
The ‘SHAPE’ research study is a multi-site trial, working in collaboration with Norway and the UK. This study aims to test a new online training and support group for people in the early stages of dementia and e-leaning programme for care partners.
What does the study involve?
Participants will be randomly allocated to either the (a) intervention or (b) control group of the research study.
a) The intervention group: People with dementia will be invited to an online training and support group, comprising of 10 weekly online sessions, each lasting up to 2 hours. During the group, people will be supported to develop skills in areas including decision-making, symptom management, healthy habits adapting and coping. Care partners will receive an e-learning program following similar themes with some additional support.
b) The control group: Like with a lot of research studies, some participants will be randomised to the control group, which means they will not receive the intervention from our research team. However, after study completion, both participants and families can receive the e-learning course comprising of the educational material used in the group.
All participants and care partners will also be asked to attend 3 assessment sessions to answer questionnaires relating to health and wellbeing.
What are the benefits of this study?
We hope that your participation in this study will provide you and your care partner with more information on dementia and strategies to make positive changes to health and wellbeing. Some participants might also benefit from the social aspects of attending an online group session, such as sharing and listening to different strategies to promote living well with dementia. Additionally, the information gained from this research study could positively direct future research as well as influence the support offered to people in the early stages of dementia and their support network.
SHAPE groups have been running for the past few months and participants have contributed with enthusiasm and engagement:
‘Joining the SHAPE group each week helped me understand how important it is to have fun in life, exercise regularly and read more books. I learned so much about dementia and feel more confident sharing my experience with my family.’
This study may be suited to you if:
If you are interested in hearing more about the study, please fill out the form below or contact us directly on 02 9399 1116 or shape@neura.edu.au.
Contact
For further information about this research study, please contact us on:
Jana Koch (Research Assistant)
E-mail: j.koch@neura.edu.au
Phone: (02) 9399 1116
This research study is funded by The National Health and Medical Research Council. This study has been approved by UNSW human research ethics committee, reference number: HC190440.
This systematic review and meta-analysis explores reproductive outcomes following a haematological cancer requiring HSCT. This meta-analysis reflects low pregnancy rates for cancer survivors desiring a family. However, live births are improving over time with new technology and novel therapies. Hence, female cancer patients should be offered timely discussions, counselling and education around fertility preservation options prior to starting treatment with gonadotoxic therapy.